MARKET WIREYahoo! Finance Canada • 6h ago
Adagene Inc. (ADAG) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
Why ADAG Stock dropped -6.34% Today — RQD Quant Desk Flash
$2.51 -6.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.48
Adagene Inc. (ADAG) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $177.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ADAG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ADAG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Adagene Inc. (NASDAQ: ADAG) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.51 (-6.34% 1D, market cap $177.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ADAG ranks #852 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ADAG compare to ANTX and ORMP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADAG carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANTX (AN2 Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $177.0M) and ORMP (Oramed Pharmaceuticals Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -7.8%, cap $176.0M). Among the 5-stock peer group, ADAG leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ADAG?
▼
Per ADAG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818838), Adagene Inc. generated $7.7M in revenue (+7332.8% YoY), -$17.6M in net income, and -$15.7M in free cash flow against $78.3M in total assets and $1.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.48 (-1.33%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADAG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY ADAG SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (27% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.76-25.4% Next Q
38
Q2 (-2Q)Grade E$2.06+17% Next Q
35
Q3 (-1Q)Grade E$2.41+4.1% Next Q
33
CurrentGrade E$2.51-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ADAG Turnaround Squeeze
While ADAG currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.05) and Max Pain ($2.64) forces dealer call-delta covering toward $5.09.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADAG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ADAG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ADAG Stock dropped -6.34% Today — RQD Quant Desk Flash
Adagene Inc. (ADAG) dropped -6.34% to $2.51, trading at 34% of its 52-week range ($1.3 – $4.85). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 34% of its 52-week range ($1.3 – $4.85) with RSI-14 at 43.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.51 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ADAG Headlines & Catalysts
MARKET WIREStockInvest.us • 9h ago
Adagene Stock Price Forecast. Should You Buy ADAG?StockInvest.us report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 12h ago
Adagene Inc. Estimates – NASDAQ:ADAGTradingView report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 15h ago
The first patient has received two drugs together in a colorectal cancer study.Stock Titan report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 18h ago
HC Wainwright & Co. reiterates Buy rating on Adagene, $7 price targetTradingView report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 21h ago
Adagene (ADAG) Slips to $2.76 as Shares Test Lower End of Recent Range - Long Setup Ideashttps://www.dars.gov.et/ report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Chardan Capital maintains Buy rating on Adagene, $9 price targetTradingView report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Adagene Inc. (ADAG) Stock Price Prediction for 2026, 2030-2040Traders Union report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 1d ago
What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline?Incyte (NasdaqGS: INCY) and Adagene have started first patient dosing in a Phase 1 trial combining INCA33890 with muzastotug for microsatellite stable colorectal cancer. The early stage study is testing the investigation
MARKET WIREYahoo • 5d ago
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal CancerPhase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and SU
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADAG)
- ✓Walkthrough of ADAG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ADAG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.79%▼ DESCENDING CHANNEL
2026-10-30O $2.67H $2.69L $2.46C $2.51VOL 79.7K
RES: $3.18SUP: $1.84SMA50: $3.05SMA200: $3.42
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ADAG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ADAG today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ADAG. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ADAG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADAG)
Health Care Rank #852 of 1016
⚔️ ANTX vs ADAG Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ADAG vs. ANTX, ORMP, UPB, SION)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Adagene Inc. (ADAG) ranks #852 by composite RQD confidence (30/100, grade E) and #594 by equity capitalization ($177.0M). Within this direct 5-issuer industry benchmark cohort, ADAG leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. ANTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ADAG at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ADAG
ACTIVE
Adagene Inc. | E | 30/100 | — | — | -35.0% | -6.34% | $177.0M | Benchmark Subject |
| ANTX AN2 Therapeutics Inc. | D | 46/100 | — | — | -35.0% | -3.41% | $177.0M | /antx-vs-adag → |
| ORMP Oramed Pharmaceuticals Inc. | D- | 41/100 | — | 0.7% | -7.8% | -2.84% | $176.0M | /ormp-vs-adag → |
| UPB Upstream Bio Inc. | D- | 42/100 | — | — | -35.0% | +4.28% | $179.1M | /upb-vs-adag → |
| SION Sionna Therapeutics Inc. | D- | 38/100 | — | — | -28.3% | -3.25% | $180.8M | /sion-vs-adag → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818838In its most recent audited fiscal period (FY2025, filed 2025-12-31), Adagene Inc. (ADAG) reported GAAP revenue of $7.7M (+7332.8% vs. FY2024 revenue of $103.2K , and -57.6% cumulative change since FY2023) , GAAP net income of -$17.6M, operating cash flow of -$15.7M, and free cash flow of -$15.7M (+47.3% YoY). On the balance sheet, ADAG closed FY2025 with $78.3M in total assets against $1.1M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.7M | -$17.6M | -$15.7M | -$15.7M | $78.3M | $1.1M |
| FY2024 (FY) | 2024-12-31 | $103.2K | -$33.4M | -$29.7M | -$29.7M | $89.3M | $417.3K |
| FY2023 (FY) | 2023-12-31 | $18.1M | -$18.9M | -$28.5M | -$28.5M | — | — |
3. ADAG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ADAG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Adagene Inc. (NASDAQ: ADAG) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.51 (-6.34% 1D, market cap $177.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ADAG ranks #852 in composite RQD confidence.
How does ADAG compare to ANTX and ORMP in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADAG carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANTX (AN2 Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $177.0M) and ORMP (Oramed Pharmaceuticals Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -7.8%, cap $176.0M). Among the 5-stock peer group, ADAG leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ADAG?
Per ADAG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818838), Adagene Inc. generated $7.7M in revenue (+7332.8% YoY), -$17.6M in net income, and -$15.7M in free cash flow against $78.3M in total assets and $1.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ADAG trading relative to its 50-day, 200-day, and 52-week technical levels?
ADAG last traded at $2.51 (-6.34% on volume of 79,692 shares), positioning the stock -17.70% below its 50-day simple moving average ($3.05) and -26.61% below its 200-day simple moving average ($3.42). Across its 52-week range of $1.30 to $4.85, ADAG sits at the 34.1% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.20 to $2.82).
ADAG Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ADAG stock moving today?
Why ADAG Stock dropped -6.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ADAG — Adagene Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:41:58Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ADAG scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 3/20 (ROIC -35%; FCF yield -8.85%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 0.2; Piotroski F 5/9; Debt/Equity 0.03).
For a prospective investor, the weakest pillars are the cash engine and insider conviction, both scoring 3 of 20. The negative ROIC and negative FCF yield indicate the business is currently consuming capital rather than generating it, per the Roarable RQD rating and market data. The Altman Z-Score of 0.2 sits in the distress territory of the source's framing, and the Piotroski F-Score of 5/9 signals mixed rather than strong fundamental health. The low Debt/Equity of 0.03 is the most favorable forensic datapoint, indicating limited leverage, though the cash-burn trend is the central concern. Upside drivers would need to come from clinical or partnership catalysts rather than current earnings. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $7.7M | $-21.4M | $-17.6M | N/A | $-15.7M | $74.5M | $1.1M |
| FY 2024 | $0.1M | $-36.0M | $-33.4M | N/A | $-29.7M | $85.2M | $0.4M |
| FY 2023 | $18.1M | $-23.7M | $-18.9M | N/A | $-28.5M | N/A | N/A |
Per the SEC financials, operating losses persisted across all three reported periods, with FY 2025 operating income at $-21.4M against revenue of $7.7M. Market data shows operating and net margins of -60%, a gross margin of 0%, and ROIC of -35%. The Altman Z-Score of 0.2 and Piotroski F-Score of 5/9 are reported in the Roarable RQD rating, alongside Debt/Equity of 0.03. Cash declined from $85.2M in FY 2024 to $74.5M in FY 2025 while debt rose from $0.4M to $1.1M.
Recent Catalysts & News Wire Analysis
Per the recent news wire, several items reference ADAG, all flagged YELLOW with impact label MARKET WIRE. Headlines include a Yahoo! Finance Canada market report, a StockInvest.us forecast, a TradingView estimates page, and a Stock Titan item reporting that the first patient has received two drugs together in a colorectal cancer study. A separate item reports HC Wainwright & Co. reiterating a Buy rating with a $7 price target. A further item reports shares slipping to $2.76 while testing the lower end of a recent range. The news feed contains no proprietary risk signals. Note that one item's summary field references an unrelated domain rather than a substantive description, and should be treated as unverified. The Butterfly supply-chain graph reports no proprietary signals.
Open Questions
- What is the company's cash runway given FY 2025 FCF of $-15.7M against a reported cash balance of $74.5M?
- What specific clinical programs, partnerships, or milestones drive revenue, and what is their timing?
- What explains the rise in debt from $0.4M to $1.1M between FY 2024 and FY 2025?
- Why are P/E, EPS, and EV/EBITDA unavailable, and what is the company's valuation on forward cash flow?
- What institutional or insider positioning exists, given that holder and analyst datasets are empty?
ADAG Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Adagene Inc. (ADAG) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago
Adagene Inc. (ADAG) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 9h ago
Adagene Stock Price Forecast. Should You Buy ADAG? StockInvest.us report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 12h ago
Adagene Inc. Estimates – NASDAQ:ADAG TradingView report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 15h ago
The first patient has received two drugs together in a colorectal cancer study. Stock Titan report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 18h ago
HC Wainwright & Co. reiterates Buy rating on Adagene, $7 price target TradingView report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 21h ago
Adagene (ADAG) Slips to $2.76 as Shares Test Lower End of Recent Range - Long Setup Ideas https://www.dars.gov.et/ report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Chardan Capital maintains Buy rating on Adagene, $9 price target TradingView report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Adagene Inc. (ADAG) Stock Price Prediction for 2026, 2030-2040 Traders Union report covering Adagene Inc. (ADAG) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ADAG Bull vs. Bear Conversation Board — What's Your Call at $2.51?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADAG 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $2.21 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ADAG (E • RQD 30/100) a Buy at $2.51?
Welcome to the ADAG (Adagene Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.96 (-21.9%)
Spot @ $2.51 Pump the brakes on ADAG — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ADAG, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Adagene Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $3.01 (+19.9%)
Spot @ $2.51 ADAG cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ADAG, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.51 (52-wk range $1.30 - $4.85), any beat on forward guidance forces shorts and underweight funds to chase.